Live QA session at "Aktier – Småbolagsjakten " November 20 at 19:00 CET

Uppsala, Sweden, November 6. 2017. The Facebook Group " Aktier – Småbolagsjakten " organizes a live QA session with Biovica International's CEO Anders Rylander on November 20, 2017 between 19.00 - 20.00.

For more information follow the link https://www.facebook.com/groups/smabolagsjakten/

During the live QA session, you will be given the opportunity to ask questions directly to the company management in Swedish or English. Answers will then be given in English.

To participate in the session, you must first become a  member in the Facebook group "Aktier – Småbolagsjakten". Apply for membership by submitting a membership request in good time to be sure to participate in the event. To do this, click the green "+ Join Group" button on the "Aktier – Småbolagsjakten " Facebook page.

" Aktier – Småbolagsjakten " is the largest Facebook group in the Nordic region, focusing on publicly traded small cap companies. The group has over 30,000 members.

 

For more information contact:

Cecilia Driving, CFO Biovica
Tel.: +46 (0)73 125 92 47
Email: ceclia.driving@biovica.com

 

About Biovica

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum® assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality.

Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum® is CE-labeled and MPA-registered. Appointed Certified Adviser to the company is FNCA Sweden AB.

Read more:  www.biovica.com

Tags:

About Us

Biovica develops and commercializes blood-based biomarker assays that improve monitoring of modern cancer therapies and predict patient outcome. The company’s DiviTum™ assay, a test for accurately measuring cell proliferation, has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. Biovica aims to make best-possible-treatment from day one a reality. Biovica collaborates with world-leading cancer institutes as well as pharmaceutical companies launching next-generation therapies. The company is ISO 13485 certified for Quality Management Systems. DiviTum™ is CE-labeled and MPA-registered.

Subscribe

Documents & Links